Today, I'm joined by Geoff Cook, CEO of Noom.
Evolved from behavior change app to clinical health platform, Noom combines personalized coaching with medications like GLP-1s to forge better habits and drive long-term health outcomes.
In this episode, we discuss using medication as a catalyst for behavior change.
We also cover:
Subscribe to the podcast → insider.fitt.co/podcast
Subscribe to our newsletter → insider.fitt.co/subscribe
Follow us on LinkedIn → linkedin.com/company/fittinsider
Website: www.noom.com
Programs for weight loss and proactive health available
-
The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.
Fitt Talent: https://talent.fitt.co/
Consulting: https://consulting.fitt.co/
Investments: https://capital.fitt.co/
Chapters:
(00:00) Introduction
(01:30) What's changed at Noom
(02:00) Revenue shift
(03:25) GLP-1s as catalyst
(04:20) Food noise silence
(05:35) Discontinuation rates
(06:35) Medication to maintenance
(07:00) Microdosing GLP-1s
(08:35) Challenges and strategies
(09:50) Self-experimentation & preventative health
(12:20) Other supplements
(14:05) Stacking habits
(15:35) What belongs in clinical care?
(16:20) Litmus test
(17:20) Research investment and peer-reviewed studies
(18:25) Largest microdose dataset in the world
(19:30) Virtuous loop
(20:30) Cue, micro-habit, reward framework
(21:25) Gamification
(22:32) Behavior change foundation
(24:00) Condition advantage over competitors
(26:00) Women's health, blood testing, & category expansion
(26:35) Behavior, diagnostics, and clinical care
(28:15) Blood testing for proactive health
(29:20) Care stacks and vertical integration trends
(31:10) IPO timeline and public market readiness
(32:35) 2026 goals
(33:40) Conclusion
